SPOTLIGHT -
EP. 1: Looking Ahead to the Next Game-Changer in Lung Cancer
EP. 2: CAR T-Cell Therapy in Lung Cancer
EP. 3: Immunotherapy: Potential for Higher Cure Rates in Lung Cancer
EP. 4: Applying Immunotherapy Learnings in Melanoma to Lung Cancer
EP. 5: Checkpoint Inhibition Squamous Cell and Nonsquamous Cell NSCLC
EP. 6: Activity of Afatinib in Lung Cancer
EP. 7: LUX-Lung 8: Afatinib Survival Benefit in Squamous NSCLC
EP. 8: Benefits of Liquid Biopsies in Lung Cancer
EP. 9: EGFR-Resistant Disease in Lung Cancer
EP. 10: Role of Gefitinib in EGRF-Mutant NSCLC
EP. 11: Changing Treatment Landscape in Advanced Lung Cancer
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
